1. Developing clinical trials for biosimilars;Bui;Semin Oncol,2014
2. Biosimilars: a multidisciplinary perspective;Khraishi;Clin Ther,2016
3. Interruption of Sneddon-Wilkinson subcorneal pustulation with infliximab;Kretschmer;Case Rep Dermatol,2017
4. Safety considerations of biosimilars;McKinnon;AustPrescr,2016
5. U.S. Food and Drug Administration. Report a problem to the Center for Biologics Evaluation and Research [Internet]. 2020 cited 2020 April 21]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/report-problem-center-biologics-evaluation-research.